



ASX Release

11 December 2017

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 45
108 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
Web: www.zeldatherapeutics.com

Contacts

Corporate

Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Directors

Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

ASX Code:

ZLD

Ordinary Shares:

754,841,934

Options:

48,000,000

6,000,000 (\$0.04 - 6/2/2020 -
subject to vesting conditions)
2,000,000 (\$0.04 - 6/2/2020)
40,000,000 (\$0.03125-17/11/2021)

Zelda joins with US Children's Hospital to study cannabinoid treatment in autism

- Zelda and Children's Hospital of Philadelphia (CHOP) to commence autism observational study in Pennsylvania
- Initial observational study to investigate the effects of cannabinoid treatment on autism
- Reinforces Zelda's track record in partnering with centres of excellence around the world

The Board of **Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company)** is pleased to announce it has entered into a research agreement with Children's Hospital of Philadelphia (CHOP) to study the pharmacology of cannabinoids.

This research will focus on autism with an observational trial to better understand the efficacy of treatment in existing patients and working closely with patient advocacy groups and licensed growers.

This study will leverage CHOP's extensive research infrastructure and is designed to capture a number of key efficacy and safety measures including bioanalytical studies.

This initial study will lay the groundwork for a possible future clinical trial to generate high quality, robust and acceptable data to validate the extensive positive anecdotal data amongst patient populations.

This will be an important Unites States based study, and may become a key milestone in the ongoing study of cannabinoids in controlled, clinical settings.

The observational study is expected to commence in early 2018, with preliminary results anticipated within six months. The ultimate goal is to describe cannabinoid disposition in pediatric patients, and identify compounds that may demonstrate efficacy in the treatment of pediatric autism.

The observational study builds on the formulations and positive results the Company has previously announced from its Chilean autism observational study, underpinned by the US and Chilean patient data that Zelda from those studies.

Harry Karelis, Executive Chairman said *“We are very excited to be entering into this research collaboration with CHOP. Through this alliance, we have the potential to deliver very robust clinical trial data which we hope opens up cannabinoids as a safe, effective and affordable treatment option for patients in need. This collaboration is a continuation of our focus on forming world-class partnerships and positions Zelda as one of the few, global biopharmaceutical companies operating in the cannabinoid space. Zelda has tremendous opportunities ahead and we are all very excited to be commencing a number of clinical trials in 2018.”*

Erica Daniels, Autism Advocate and Founder of Hope Grows for Autism said *“For too long, patients and their families have been missing out on genuine therapeutic options with the potential to transform lives. I am thrilled that I have been involved in bringing together CHOP and Zelda to try and make a difference.”*

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.

About Children’s Hospital of Philadelphia CHOP (www.chop.edu)

Children's Hospital of Philadelphia (CHOP) is the USA’s first hospital devoted exclusively to the care of children. Since its start in 1855, CHOP has been the birthplace for countless breakthroughs and dramatic firsts in pediatric medicine. Built on a foundation of delivering safe, high-quality, family-centered care, the Hospital has fostered medical discoveries and innovations that have improved pediatric healthcare and saved countless children’s lives. Today, families facing complex conditions come to CHOP from all over the world, and its compassionate care and innovation has repeatedly earned CHOP a spot on the *U.S. News & World Report's* Honor Roll of the nation's best children's hospitals.